This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
Canopy Growth (CGC) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions and Medical-Surgical Solutions segments.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $15.08, marking a -1.71% move from the previous day.
Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?
by Sanghamitra Saha
"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $15.76, marking a +0.13% move from the previous day.
Constellation Brands (STZ) Tops Q4 Earnings & Sales Estimates
by Zacks Equity Research
Constellation Brands (STZ) reports strong fourth-quarter fiscal 2020 results, driven by continued strength in the beer business and gains in the wine & spirits segment.
The Zacks Analyst Blog Highlights: UBER, ZM, MSFT, STZ and CGC
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UBER, ZM, MSFT, STZ and CGC
Booze Takes The Edge Off The Coronavirus
by Daniel Laboe
Alcohol sales are flying this month and online delivery services are a primary catalyst
Buy Corona Maker Constellation (STZ) Stock Before Q4 Earnings Amid Surge?
by Benjamin Rains
Constellation Brands (STZ) shares have surged 40% in the last week. So now might be time for investors to consider buying the Corona beer maker's stock before it reports its Q4 fiscal 2020 results on Friday, April 3...
Are Marijuana Stocks & ETFs Coronavirus-Proof?
by Sanghamitra Saha
Marijuana companies are witnessing robust demand amid the coronavirus outbreak. Time to buy some earlier-battered marijuana stocks and ETFs?
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Here's How Coronavirus Can Impact Cannabis Industry
by Zacks Equity Research
Marijuana should be avoided during the pandemic as users share marijuana joints, which may increase the spread of the virus.
Marijuana is Growing Cash, Can We Get In?
by Panel Of Zacks Experts
The market is still dealing with COVID19 (coronavirus issues) so we're talking about how marijuana is still a market mystery, Marijuana Innovators Editor Dave Borun joins us to shed some light on the subject.
How Canopy Growth (CGC) Stock Stands Out in a Strong Industry?
by Zacks Equity Research
Canopy Growth (CGC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
Are Options Traders Betting on a Big Move in Canopy Growth (CGC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings
by Zacks Equity Research
Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter
Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth Corporation (CGC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $22.33, marking a +1% move from the previous day.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $23.52 in the latest trading session, marking a -1.67% move from the prior day.
What's in Store for Pot Stocks This Year?
by Nitish Marwah
Increasing tolerance, financial protection, credit availability and legal votes have shaped America's hemp industry lately.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $24.56 in the latest trading session, marking a +1.82% move from the prior day.